^
Association details:
| Biomarker: | AHNAK2 mutation + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Deleterious AHNAK2 Mutation as a Novel Biomarker for Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer
Published date:
03/10/2022
Excerpt:
...we compared ICI response between patients with TP53 mutation only and patients with both TP53 and AHNAK2 mutation. As shown in Figure 2D, patients with AHNAK2 and TP53 co-mutations achieved a higher ORR than patients with TP53 mutation only.
DOI:
https://doi.org/10.3389/fonc.2022.798401
